Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SELL | P14151 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733075 | 1.00 | POLB (0.43) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL572181 | 1.00 | POLB (0.43) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL23825900 | 0.89 | FASN (0.38) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL1543589 | 0.89 | FASN (0.38) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL12436014 | 0.84 | ATM (0.47) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL22722029 | 0.84 | ATM (0.47) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL12436833 | 0.84 | ATM (0.47) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL22722017 | 0.84 | EPHX2 (0.56) | EPHX2EPHX1NPC1SMN1; SMN2RAB9A | |
| SCHEMBL12436784 | 0.84 | EPHX2 (0.56) | EPHX2EPHX1NPC1SMN1; SMN2RAB9A | |
| SCHEMBL6658887 | 0.83 | EPHX2 (0.50) | POLBEPHX2MMP2MMP8EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023163140-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-08-31 | — | — | WO | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | ARRIEN PHARMACEUTICALS LLC | 2020-04-30 | — | — | US | disclosed |
| EP-2706853-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9290490-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| CN-102046603-B | [4- (1-amino-ethyl) -cyclohexyl ] -methyl-amine and [6- (1-amino-ethyl) -tetrahydro-pyran-3-yl ] -methyl-amine derivatives as antibacterial agents | ACTELION PHARMACEUTICALS LTD | 2014-08-13 | — | — | CN | disclosed |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-05-29 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8173699-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| CN-102046603-A | [4- (1-amino-ethyl) -cyclohexyl ] -methyl-amine and [6- (1-amino-ethyl) -tetrahydro-pyran-3-yl ] -methyl-amine derivatives as antibacterial agents | ACTELION PHARMACEUTICALS LTD | 2011-05-04 | — | — | CN | disclosed |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | ANDERSKEWITZ RALF | 2010-07-29 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1737857-A1 | PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | POLB 1517/4885EPHX2 4373/4885MMP2 1667/4885 |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | MALT1, IL1B, RORC | POLB 1793/4885EPHX2 561/4885MMP2 1961/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | POLB 1918/4885EPHX2 155/4885MMP2 174/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | POLB 1575/4885EPHX2 1135/4885MMP2 345/4885 |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | POLB 3559/4885EPHX2 4434/4885MMP2 1463/4885 |
| US-20140148474-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | POLB 855/4885EPHX2 1568/4885MMP2 3029/4885 |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | PAICS, MCL1, TP53 | POLB 357/4885EPHX2 3802/4885MMP2 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.